N-myc, a strong predictor of poor outcomes in patients with neuroblastoma, acts as a downstream effector in PI3K/AKT mediated oncogenic transformations in neuroblastoma cells in vitro and in vivo[17]. This evidence concerns the gene MYCN and neuroblastoma.